Jade Biosciences, Inc.

NASDAQ: JBIO · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0001798749Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 60DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$127.4M

Employees

Market cap

$701.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$127.4M-$127.4M2025

Operating income-$113.5M-$113.5M2025

Total assets$349.8M$349.8M2025

Liabilities$17.3M$17.3M2025

Equity$332.5M$332.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Jade Biosciences, Inc. earned -$127.4M in FY2025 net income.

Peers · Healthcare

Prime Medicine, Inc.37D Tactile Systems Technology, Inc.82B+Bioventus Inc.66B Ironwood Pharmaceuticals, Inc.79B+

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEOTom Frohlich

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: JBIO

Employees50

IPO date2025-04-29

Latest filings

8-K2026-07-01 8-K2026-06-26 8-K2026-06-11 8-K2026-06-04 8-K2026-06-01 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.